Correct usage and recommended dosage of capmatinib

Capmatinib (English generic namecapmatinib, English trade name Tabrecta), produced by Novartis Pharmaceuticals and approved by the US FDA, is a targeted drug specifically targeting mesenchymal epithelial transition (MET) exon 14 skipping mutations. To ensure that patients can use this drug safely and effectively, this article provides detailed usage and dosage guidance for capmatinib.

Capmatinib is taken orally, by swallowing the tablet directly. To ensure stable release and absorption of the drug, patients should swallow the tablets whole and avoid breaking, crushing, or chewing.

In terms of dosage, the usual dosage of capmatinib is 400 mg twice daily. However, it should be noted that the specific dosage for each patient should be customized by the doctor based on factors such as age, weight, and condition. Therefore, patients should consult their doctor in detail before starting medication to determine the dosage that is suitable for them. If certain adverse reactions occur while you are taking this medication, your doctor may change your dose, temporarily stop, or permanently stop treatment.

When using capmatinib, be sure to maintain the accuracy and regularity of medication, and do not adjust the dosage or medication time at will, so as not to affect the efficacy or increase the risk. If you miss a dose or vomit after taking the medicine, you do not need to take it again. You only need to continue taking the medicine at the next scheduled time.

During the medication, patients should pay close attention to physical reactions. If serious adverse reactions such as difficulty breathing, palpitations, and chest pain occur, they should seek medical treatment immediately and inform the doctor that they are using capmatinib.

It is worth noting that capmatinib is not currently approved in China and patients need to purchase it from overseas. As a reminder, be sure to purchase through formal channels to ensure the safety and authenticity of medicines.